Prothena Corporation plc

Research Prothena Corporation plc (PRTA) on Bullrun: market cap USD 521.96M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPRTA
• ExchangeNASDAQ
• CountryIreland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 521.96M
• Financial periodFY2025
• RevenueUSD 9.68M
• Revenue growth-92.8%
• Net income-USD 244.09M

Valuation Snapshot

latest market cap is USD 521.96M.

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.

Frequently asked questions

What is Prothena Corporation plc's market cap?

Prothena Corporation plc's market capitalization is USD 521.96M.

What does Prothena Corporation plc do?

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.